CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
(4) - EconoTimes)
CAMBRIDGE, Mass., May 31, 2017 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, granted equity awards on May 31, 2017, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to ten individuals hired by Sarepta in May 2017. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
The employees received, in the aggregate, options to purchase 57,820 shares of Sarepta's common stock. The options have an exercise price of $29.84 per share, which is equal to the closing price of Sarepta's common stock on May 31, 2017. One-fourth of the shares underlying each employee’s option will vest on the one year anniversary of his or her date of hire and thereafter 1/48th of the shares underlying each employee’s option will vest monthly, such that the shares underlying the option granted to each employee will be fully vested on the fourth anniversary of his or her date of hire, in each case, subject to each such employee’s continued employment with Sarepta on such vesting dates.
About Sarepta Therapeutics
Sarepta Therapeutics is a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please visit www.sarepta.com.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Media and Investors: Sarepta Therapeutics, Inc. Ian Estepan, 617-274-4052 [email protected] or W2O Group Brian Reid, 212-257-6725 [email protected]
